About ERBA Diagnostics (OTCMKTS:ERBA)
ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures and markets diagnostic test kits, or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology and diabetes testing. The Company's segments include Domestic and European. The domestic region contains its subsidiaries located in the United States and in Latin American and corporate operations. The European region contains its subsidiary located in Italy. Its tests are based on a range of technologies, including Enzyme Linked ImmunoSorbent Assay (ELISA) technology, clinical chemistry, hematology and cell separation, as well as high performance liquid chromatography (HPLC) separations, all of which are clinical testing methodologies used across the world. It also designs and manufactures laboratory instruments that perform the tests.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$26.39 million
Price / Sales0.41
Cash Flow$0.03 per share
Price / Cash7.02
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
ERBA Diagnostics (OTCMKTS:ERBA) Frequently Asked Questions
What is ERBA Diagnostics' stock symbol?
ERBA Diagnostics trades on the OTCMKTS under the ticker symbol "ERBA."
How were ERBA Diagnostics' earnings last quarter?
ERBA Diagnostics Inc (OTCMKTS:ERBA) announced its earnings results on Wednesday, August, 5th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.01. The firm earned $5.90 million during the quarter, compared to analysts' expectations of $5.16 million. View ERBA Diagnostics' Earnings History.
Who are some of ERBA Diagnostics' key competitors?
Some companies that are related to ERBA Diagnostics include Chiasma (CHMA), Evoke Pharma (EVOK), Presbia (LENS), Immutep (IMMP), BioSig Technologies (BSGM), Imprimis Pharmaceuticals (IMMY), AzurRx BioPharma (AZRX), Vical (VICL), Caladrius Biosciences (CLBS), Invivo Therapeutics (NVIV), Proteon Therapeutics (PRTO), Oncobiologics (ONS), Cleveland BioLabs (CBLI), Genocea Biosciences (GNCA), Pernix Therapeutics (PTX), ReWalk Robotics (RWLK), Prana Biotechnology (PRAN) and EnteroMedics (RSLS).
Who are ERBA Diagnostics' key executives?
ERBA Diagnostics' management team includes the folowing people:
- Suresh H. Vazirani, Executive Chairman of the Board (Age 66)
- David Barka, Interim Chief Executive Officer (Age 36)
- Chandra Krishnan, Senior Vice President - Global Sales, Marketing and Business Development
- Nikhil Vazirani, Director
- Gerald E. Gallwas, Independent Director (Age 79)
- David M. Templeton, Independent Director (Age 62)
How do I buy ERBA Diagnostics stock?
Shares of ERBA Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ERBA Diagnostics' stock price today?
One share of ERBA Diagnostics stock can currently be purchased for approximately $0.22.
How big of a company is ERBA Diagnostics?
ERBA Diagnostics has a market capitalization of $22.04 million and generates $26.39 million in revenue each year. The company earns $440,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.
How can I contact ERBA Diagnostics?
ERBA Diagnostics' mailing address is 2140 N Miami Ave, MIAMI, FL 33127-4916, United States. The company can be reached via phone at +1-305-3242300 or via email at [email protected]
MarketBeat Community Rating for ERBA Diagnostics (ERBA)MarketBeat's community ratings are surveys of what our community members think about ERBA Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
ERBA Diagnostics (OTCMKTS:ERBA) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
ERBA Diagnostics (OTCMKTS:ERBA) Earnings History and Estimates Chart
ERBA Diagnostics (OTCMKTS ERBA) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/5/2015||Q215||($0.02)||($0.01)||$5.16 million||$5.90 million||View||N/A|
|5/18/2015||Q115||$0.01||($0.01)||$8.10 million||$12.60 million||View||N/A|
|8/12/2014||Q214||$0.01||$6.74 million||$7.54 million||View||N/A|
|11/14/2012||Q312||($0.01)||$4.06 million||$3.80 million||View||N/A|
ERBA Diagnostics (OTCMKTS:ERBA) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ERBA Diagnostics (OTCMKTS:ERBA)
No dividend announcements for this company have been tracked by MarketBeat.com
ERBA Diagnostics (OTCMKTS ERBA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 88.10%
Institutional Ownership Percentage: 0.02%
ERBA Diagnostics (OTCMKTS ERBA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/15/2014||Gopalkrishnan Mohan||CEO||Buy||5,000||$2.89||$14,450.00|| |
ERBA Diagnostics (OTCMKTS ERBA) News Headlines
ERBA Diagnostics (OTCMKTS:ERBA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
ERBA Diagnostics (OTCMKTS ERBA) Stock Chart for Thursday, December, 14, 2017